JP2004531227A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004531227A5 JP2004531227A5 JP2002559678A JP2002559678A JP2004531227A5 JP 2004531227 A5 JP2004531227 A5 JP 2004531227A5 JP 2002559678 A JP2002559678 A JP 2002559678A JP 2002559678 A JP2002559678 A JP 2002559678A JP 2004531227 A5 JP2004531227 A5 JP 2004531227A5
- Authority
- JP
- Japan
- Prior art keywords
- dye
- compartment
- protein
- clc
- see
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 14
- 239000000975 dye Substances 0.000 description 11
- 239000000126 substance Substances 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 8
- 101710135663 H(+)/Cl(-) exchange transporter 7 Proteins 0.000 description 7
- 108091006146 Channels Proteins 0.000 description 6
- 102100028685 H(+)/Cl(-) exchange transporter 7 Human genes 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000002504 synaptic vesicle Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000011045 Chloride Channels Human genes 0.000 description 4
- 108010062745 Chloride Channels Proteins 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 230000020477 pH reduction Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229930193140 Neomycin Natural products 0.000 description 3
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 3
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229960004927 neomycin Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- 108020004440 Thymidine kinase Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 208000002865 osteopetrosis Diseases 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 1
- 101000583086 Bunodosoma granuliferum Delta-actitoxin-Bgr2b Proteins 0.000 description 1
- 102000034573 Channels Human genes 0.000 description 1
- 102100034477 H(+)/Cl(-) exchange transporter 3 Human genes 0.000 description 1
- 101710135680 H(+)/Cl(-) exchange transporter 3 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 230000005786 degenerative changes Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- IRSCQMHQWWYFCW-UHFFFAOYSA-N ganciclovir Chemical compound O=C1NC(N)=NC2=C1N=CN2COC(CO)CO IRSCQMHQWWYFCW-UHFFFAOYSA-N 0.000 description 1
- 229960002963 ganciclovir Drugs 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10102977A DE10102977A1 (de) | 2001-01-23 | 2001-01-23 | Testsystem zur Entwicklung von Therapeutika, insbesondere von Wirkstoffen zur Behandlung von Osteoporose |
| PCT/DK2002/000038 WO2002059612A2 (en) | 2001-01-23 | 2002-01-17 | Animal model and cell-line expressing modified chlorine channel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004531227A JP2004531227A (ja) | 2004-10-14 |
| JP2004531227A5 true JP2004531227A5 (enExample) | 2007-10-18 |
| JP4138485B2 JP4138485B2 (ja) | 2008-08-27 |
Family
ID=7671497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002559678A Expired - Fee Related JP4138485B2 (ja) | 2001-01-23 | 2002-01-17 | 治療薬剤、特に骨粗しょう症を治療するための有効活性化合物を開発するための試験システム |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7534425B2 (enExample) |
| EP (1) | EP1360204B1 (enExample) |
| JP (1) | JP4138485B2 (enExample) |
| AU (1) | AU2002224759A1 (enExample) |
| DE (1) | DE10102977A1 (enExample) |
| WO (1) | WO2002059612A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1360504T3 (da) * | 2001-01-23 | 2007-01-29 | Pharmos Bioscience As | Fremgangsmåde til screening af forbindelser for aktivitet ved behandling af en osteoclast-relateret knoglesygdom |
| WO2003062821A1 (en) * | 2002-01-23 | 2003-07-31 | Bristol-Myers Squibb Company | Modulators of the clc-7 chloride channel and methods for their identification and use in the treatment and prevention of osteoporosis and related disease states |
| WO2003065871A2 (en) | 2002-02-04 | 2003-08-14 | Millennium Pharmaceuticals Inc. | Methods and compositions for treating hematological disorders |
| GB0227243D0 (en) * | 2002-11-21 | 2002-12-31 | Univ Aberdeen | Genetic markers for bone mass |
| WO2006066064A2 (en) * | 2004-12-13 | 2006-06-22 | Monell Chemical Senses Center | A voltage-gated, ph-sensitive anion channel and its novel splice variant involved in taste sensation |
| US20080263436A1 (en) * | 2007-02-13 | 2008-10-23 | Ahrens Mark H | Methods and apparatus to reach through to business logic services |
| US8741591B2 (en) | 2009-10-09 | 2014-06-03 | The Research Foundation For The State University Of New York | pH-insensitive glucose indicator protein |
| EP2420830B1 (en) * | 2010-08-16 | 2016-11-16 | Forschungsverbund Berlin e.V. | Chloride transporter ClC-7 and cell-based screening method |
| US11060060B2 (en) | 2015-09-16 | 2021-07-13 | University of Pittsburgh—of the Commonwealth System of Higher Education | Method of making trabecular bone |
| US10640766B2 (en) * | 2017-04-12 | 2020-05-05 | Tempo Bioscience, Inc. | Biosensors for chloride ions |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5434058A (en) * | 1993-02-09 | 1995-07-18 | Arch Development Corporation | Apolipoprotein B MRNA editing protein compositions and methods |
| AU9679998A (en) * | 1997-10-01 | 1999-04-23 | Yale University | Methods to modulate blood pressure and diagnose bartter's syndrome type iii |
| SK5222001A3 (en) | 1998-10-22 | 2002-05-09 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
| US7312043B2 (en) * | 2000-07-10 | 2007-12-25 | Vertex Pharmaceuticals (San Diego) Llc | Ion channel assay methods |
-
2001
- 2001-01-23 DE DE10102977A patent/DE10102977A1/de active Pending
-
2002
- 2002-01-17 JP JP2002559678A patent/JP4138485B2/ja not_active Expired - Fee Related
- 2002-01-17 AU AU2002224759A patent/AU2002224759A1/en not_active Abandoned
- 2002-01-17 EP EP02715379.0A patent/EP1360204B1/en not_active Expired - Lifetime
- 2002-01-17 WO PCT/DK2002/000038 patent/WO2002059612A2/en not_active Ceased
-
2003
- 2003-07-18 US US10/622,377 patent/US7534425B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kim et al. | Identification of molecular markers of bipolar cells in the murine retina | |
| JP2023058651A (ja) | 多重レセプター－リガンド相互作用スクリーニング | |
| US20040219563A1 (en) | Method using gene trapped stem cells for making pathways of stem cell differentiation and making and isolating differentiated cells | |
| KR20210141536A (ko) | 타우 응집과 관련된 유전적 취약성을 식별하기 위한 CRISPR/Cas 드랍아웃 스크리닝 플랫폼 | |
| US20070259343A1 (en) | Somatic transfer of modified genes to predict drug effects | |
| EP1811023A1 (en) | Gene expressed specifically in es cells and utilization of the same | |
| US20040087014A1 (en) | Eukaryotic expression libraries and methods of use | |
| WO2018195129A1 (en) | Embryonic cell cultures and methods of using the same | |
| AU726014B2 (en) | Cell-based drug screens for regulators of gene expression | |
| Gagny et al. | Identification of the genes encoding the cytosolic translation release factors from Podospora anserina and analysis of their role during the life cycle | |
| Rohozinski et al. | Successful targeting of mouse Y chromosome genes using a site‐directed insertion vector | |
| US20200181605A1 (en) | High-throughput protein analysis method and suitable library thereof | |
| EP1911842A1 (en) | EXPRESSION VECTOR HAVING PROMOTER SEQUENCE OF Vasa HOMOLOGUE GENE DERIVED FROM MAMMAL AND USE THEREOF | |
| JP2009539352A (ja) | パーフォリン−２タンパク質 | |
| JP2000515386A (ja) | Ｋｕ欠損細胞と非ヒトトランスジェニック動物 | |
| CN116376975A (zh) | 激活异染色质基因的方法及应用 | |
| WO1999060122A1 (en) | Method for examining central nervous system diseases and method for screening remedies | |
| CN114891800B (zh) | 玉米穗长基因及其应用 | |
| CN109295000B (zh) | 一种多能干细胞形成必需蛋白crept在诱导多能干细胞中的应用 | |
| EP0467883A4 (en) | Method of physically mapping genetic material | |
| CN109423522B (zh) | 猪cd4基因功能突变位点分子育种标记的鉴定及应用 | |
| CN120137060B (zh) | 一种高效的线粒体基因甲基化修饰工具及其应用 | |
| Potluri et al. | High throughput gene complementation screening permits identification of a mammalian mitochondrial protein synthesis (ρ−) mutant | |
| JP2005528084A (ja) | 生存可能なｃ−ｋｉｔ発現細胞を単離するための道具 | |
| Fischer et al. | Visualizing loss of heterozygosity in living mouse cells and tissues |